Lantheus Holdings(US:LNTH) Prnewswireยท2025-09-11 01:46Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims centered around misleading information regarding the company's revenue outlook and market dynamics for its key product, Pylarify [1][4]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with Pylarify being a significant product used for prostate cancer diagnosis and treatment [3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives misrepresented the company's revenue projections and downplayed risks related to competition, pricing, and macroeconomic factors [4]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing earnings reports [4][5]. Financial Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [6]. Legal Process - Investors who purchased Lantheus securities during the specified class period (February 26, 2025, to August 5, 2025) have until November 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7].